Viral-vector vaccines ‘likely best with rituximab’
Researchers recommend COVID-19 vaccines associated with low release of interferon for B cell-depleted patients.
Tag: Biologics
Immunotherapy add-on ‘fails to improve survival’ in elderly with NSCLC
A real-world study shows adding a checkpoint inhibitor to chemotherapy in older patients with advanced disease doesn’t replicate the benefit seen…
Rituximab ‘impairs COVID-19 vaccine efficacy’
Two studies may help guide timing of both treatment and inoculation, rheumatologists say.
Discontinuation of infliximab in IBD ‘threatens relapse’
But the groundbreaking study finds histological remission is predictive of successful withdrawal.
Therapeutic drug monitoring tested for infliximab
The trial during induction has been carried out across a mix of patients with inflammatory diseases.
Psoriasis biologics ‘don’t raise skin cancer risk’
A registry study shows no difference in risk for patients on biologic compared with other therapies, although this might not hold for those older t…
Giant cell arteritis: What happens when biologic therapy stops?
New data on tocilizumab underlines its limitations for durable remission, a leading rheumatologist says.
Switch to infliximab biosimilar safe and effective in IBD: study
An Australian prospective study demonstrates outcomes are non-inferior to those with the originator biologic, researchers say.
Anti-IL-5 biologics effective for up to two years in severe asthma: study
Registry study shows 14% of patients with severe eosinophilic disease are 'super-responders'.
TNF blocker to be trialled as COVID-19 treatment
The Oxford University trial will take place in aged-care facilities in the UK.
